Phase 1 Single Ascending Dose Study

Phase 1 Recruiting 36 enrolled Neuramedy Co. Ltd. Seoul National University Hospital · collab

RandomizedSingle-groupTriple-blindTreatment

Summary

Phase 1, double-blind, placebo-controlled, single-centre, single ascending dose escalation study to assess safety and tolerability of a monoclonal antibody, NM-101 in healthy volunteer subject and multiple system atrophy (MSA) patients.

Timeline

Start: 2024-11-25
Primary completion: 2025-10-30
Completion: 2026-03-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NM-101	Protein / enzyme biologic	—	Intravenous

Indications

No indication recorded.